News

Destiny Pharma plc – Fundraising to raise up to £8 million

Fundraising to raise up to £8 million Destiny Pharma plc (AIM:…

Destiny Pharm plc – Agreement with Sebela Pharmaceuticals for NTCD-M3

Exclusive collaboration and co-development agreement for NTCD-M3…

Novo Holdings invests in water technology company Aquafortus

Aquafortus, a water technology company that purifies high salinity…

Novo Holdings participates in Hemab Therapeutics $135M Series B Financing

Hemab Therapeutics is a clinical-stage biotechnology company…

Methinks receives CE Marked Certification for AI-based stroke triage software

Methinks Stroke Suite is a disruptive technology that has the…

Zephyrus Innovations announces US FDA approval for its Aeroject™ 3ml safety syringe

Aeroject™ 3ml safety syringe is a single-use, affordable,…

Leucid Bio provides business update and outlook for 2023

Proprietary Lateral CAR Platform achieved pre-clinical…

Futura Medical to present MED3000 FM71 data at the European Society for Sexual Medicine Congress 2023

Futura Medical plc (AIM: FUM), a pharmaceutical company developing…

Novo Holdings Venture Investments team Newsletter

The Novo Holdings Venture Investments team has published its…

Sequana Medical announces 2022 Full Year Results and 2023 Outlook

alfapump® – successful primary endpoint read-out of North…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.